GlassScriptPhysician profile
Peter B Amsterdam
NPI 1487692570
$4,315.43
in general payments reported to CMS, 2019-2025
27 companies · $898 in 2025
The $898 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $157 · 2021: $122 · 2022: $412 · 2023: $1,020 · 2024: $1,403 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,192 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,192.44 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $833.12 | 2023-2025 | Ozempic, Wegovy |
| Boston Scientific Corporation | $624.65 | 2022-2025 | Opticross, General - Therapies, Avvigo Guidance System |
| Novartis Pharmaceuticals Corporation | $394.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $317.75 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Abbott Laboratories | $212.42 | 2021-2024 | Mitraclip, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.19 | 2019-2024 | Jardiance |
| Zoll Circulation INC | $188.55 | 2022-2025 | Therox Ds2 Console, Downstream Cartridge, Catheter |
| Pfizer INC. | $182.05 | 2024-2025 | |
| Amgen INC. | $178.64 | 2022-2024 | Repatha |
| Teleflex LLC | $174.15 | 2024 | Turnpike |
| Cardiovascular Systems INC. | $154.17 | 2019-2022 | |
| Abiomed | $144.71 | 2019 | |
| Medtronic, INC. | $141.18 | 2022-2024 | Corevalve Evolut R |
| Heartflow, INC. | $100.84 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $97.76 | 2024-2025 | Camzyos, Eliquis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $77.79 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Sanofi-Aventis U.S. LLC | $47.69 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $46.69 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.79 | 2023-2024 | |
| Esperion Therapeutics, INC. | $30.14 | 2024 | Nexletol |
| Cordis US Corp. | $23.83 | 2025 | Mynxgrip |
| Philips North America LLC | $20.00 | 2022 | |
| Biosense Webster, INC. | $16.50 | 2020 | |
| Merck Sharp & Dohme LLC | $16.28 | 2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.00 | 2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $15.43 | 2023 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $15.27 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Amsterdam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.